5 recruiting, 2 terminated, 1 active not recruiting, 1 completed. 5 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 2, Terminated 2, Active not recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Acute Lymphoblastic Leukemia With Failed Remission: new trials by email Literature Review of Acute Lymphoblastic Leukemia With Failed Remission trials Research Report on Acute Lymphoblastic Leukemia With Failed Remission
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia MB-CART19.1 - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Recurrent | Not applicable | Recruiting | King Hussein Cancer Center | 12 | 2026-02-20 | 2026-08-05 |
| Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL CD19 specific Chimeric Antigen Receptor T Cell - Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed | Early Phase 1 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2025-10-01 | 2025-08-15 |
| CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells） - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 1 | Recruiting | Rong Tao | 48 | 2024-05-31 | 2024-06-06 |
| Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia Bortezomib - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 2 | Recruiting | Instituto do Cancer do Estado de São Paulo | 50 | 2024-04-01 | 2025-05-16 |
| Determining the Mechanisms of Loss of CAR T Cell Persistence Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Not Having Achieved Remission | Recruiting | University College, London | 50 | 2023-10-18 | 2026-08-07 | |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies Venetoclax, Azacitidine, Cytarabine - Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary | Phase 1 | Recruiting | Andrew E. Place, MD | 30 | 2023-03-29 | 2026-03-12 |
| CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg) - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 1 | Terminated | Medical College of Wisconsin | 5 | 2020-10-16 | 2026-01-12 |
| Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Completed | Group for Research in Adult Acute Lymphoblastic Leukemia | 92 | 2018-07-16 | 2026-02-27 | |
| Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia Palbociclib Oral Capsule, Intrathecal Triple Therapy, Dexamethasone - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 1 | Terminated | St. Jude Children's Research Hospital | 12 | 2018-04-20 | 2020-09-01 |
| CAR-T Cell Therapy Targeting to CD19 for R/R ALL CAR T-cell therapy - Acute Lymphoblastic Leukemia With Failed Remission | Phase 1 / Phase 2 | Active not recruiting | The First Affiliated Hospital of Soochow University | 196 | 2015-12-01 | 2026-06-04 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Recurrence (3) · Leukemia, B-Cell (1) · Leukemia, Biphenotypic, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1)
Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Leukemia (10) · Leukemia, Lymphoid (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Bone Marrow Diseases (1) · Lymphoma (1)
Dexamethasone (3) · Doxorubicin (3) · Methotrexate (3) · Bortezomib (2) · Vincristine (2) · Azacitidine (1) · Calcium Dobesilate (1) · Cortisone (1) · Cytarabine (1) · Dasatinib (1) · Dexrazoxane (1) · Hydrocortisone (1) · Immunotherapy, Adoptive (1) · Leucovorin (1) · asparaginase erwinia chrysanthemi recombinant (1)
Andrew E. Place, MD (1) · Group for Research in Adult Acute Lymphoblastic Leukemia (1) · Instituto do Cancer do Estado de São Paulo (1) · King Hussein Cancer Center (1) · Medical College of Wisconsin (1) · Nationwide Children's Hospital (1) · Rong Tao (1) · St. Jude Children's Research Hospital (1) · The First Affiliated Hospital of Soochow University (1) · University College, London (1)
United States (4) · China (2) · Brazil (1) · France (1) · Jordan (1) · United Kingdom (1)
Andrew E Place, MD, PhD (1) · Depei Wu, M.D., Ph.D. (1) · Dr Zaid Abdel Rahman, Consultant,Hematology/Oncology (1) · Dr. Hasan Hashem, Consultant,Hematology/Oncology (1) · Julie-An Talano, MD (1) · Margaret Lamb, MD (1) · Persis Amrolia, BSc,MBBS,PhD (1) · Rong Tao, MD (1) · Tanja A. Gruber, MD, PhD (1) · Wellington Silva, MD PhD (1)